Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zymeworks Inc
(NY:
ZYME
)
6.430
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 15, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zymeworks Inc
< Previous
1
2
3
4
Next >
Zymeworks Announces Proposed Public Offering
January 26, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
January 19, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
January 15, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
January 05, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
December 09, 2021
From
Zymeworks Inc.
Via
Business Wire
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
December 08, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
December 01, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
November 19, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
November 09, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
November 09, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Present at Upcoming Investor Conferences
November 08, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Reports 2021 Third Quarter Financial Results
November 03, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
October 26, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
October 05, 2021
From
Zymeworks Inc.
Via
Business Wire
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
September 16, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
September 12, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Reports 2021 Second Quarter Financial Results
August 04, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
August 03, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
July 28, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Present at Ladenburg Thalmann Healthcare Conference
July 08, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Present at Jefferies Virtual Healthcare Conference
May 26, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
May 06, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Reports 2021 First Quarter Financial Results
May 05, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Succession Plan for Chief Medical Officer
April 19, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Present at Bloom Burton Healthcare Conference
April 13, 2021
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
April 10, 2021
From
Zymeworks Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.